Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-05-10
2005-05-10
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S013800, C514S014800, C514S015800, C514S016700, C514S021800, C530S317000, C530S324000, C530S325000, C530S326000, C530S327000, C530S328000, C530S329000, C530S345000
Reexamination Certificate
active
06890902
ABSTRACT:
The present invention provides a modified lactoferrin peptide which is cytotoxic, 7 to 25 amino acids in length, with three or more cationic residues and which has one or more extra bulky and lipophilic amino acids as compared to the native lactoferrin sequence, as well as esters, amides, salts and cyclic derivatives thereof as well as methods of preparing such peptides, pharmaceutical compositions containing such peptides and use of the peptides as medicaments, particularly as antibacterials or anti-tumoural agents.
REFERENCES:
patent: 5073542 (1991-12-01), Zasloff
patent: 5141851 (1992-08-01), Brown et al.
patent: 5304633 (1994-04-01), Tomita et al.
patent: 5411942 (1995-05-01), Widmer et al.
patent: 5428016 (1995-06-01), Tomita et al.
patent: 5565425 (1996-10-01), Yamamoto et al.
patent: 5593866 (1997-01-01), Hancock et al.
patent: 20030148936 (2003-08-01), Svendsen et al.
patent: 0 629 347 (1997-07-01), None
patent: WO9222317 (1992-12-01), None
patent: WO9324138 (1993-12-01), None
patent: WO9412206 (1994-06-01), None
patent: WO9401451 (1995-01-01), None
patent: WO9640768 (1996-12-01), None
patent: WO9640770 (1996-12-01), None
patent: WO9806425 (1998-02-01), None
patent: WO9806860 (1998-02-01), None
patent: WO9840091 (1998-09-01), None
patent: WO9840401 (1998-09-01), None
Yoo et al. Bovine Lactoferrin and Lactoferricin, a Peptide Derived from . . . Japanese Journal of Cancer Research. Feb. 1997, vol. 88, pp. 184-190.*
Chapple et al. Structure-Function Relationship of Antibacterial Synthetic Peptides . . . Infection And Immunity. Jun. 1998, vol. 66, No. 6, pp. 2434-2440.*
Kang et al. Structure-biological activity relationships of 11-residue highly basic peptide segment of bovine lactoferrin. International Journal Of Peptide and Protein Research. Oct. 1996, vol. 38, No. 4, pp. 357-363.*
European Patent Application Publication No. 0 510 912 A1m Oct. 28, 1992.
European Patent Application Publication No. 0 299 828 A1, Jan. 18, 1989.
Andreu et al. (1985) Biochemistry 24:1683-1688.
Bellamy et al. (1992) Journal of Applied Bacteriology 73:472-479.
Bellamy et al. (1992) Biochimica et Biophysica Acta 1121:130-136.
Bessalle et al. (1993) J. Med. Chem. 36:1203-1209.
Blondelle et al. (1992) Biochemistry 31:12688-12694.
Boman (1995) Ann. Rev. Immunol. 13:61-92.
Chen et al. (1988) FEB 236:462-466.
Cruciani et al. (1991) Proc. Natl Acad. Sci. USA 88:3792-3796.
Hancock et al. (1995) Advances in Microbial Physiol. 37:135-175.
Juretic et al. (1989) FEB 249:219-223.
Ludtke et al. (1996) Biochemistry 35:13723-13728.
Ranjalahy-Rasoloarijao et al. (1989) Int. J. Peptide Protein Res. 33:273-280.
Selsted et al. (1992) J. Biol. Chem. 267:4292-4295.
Stierandova et al. (1994) Int. J. Peptide Protein Res. 43:31-38.
Tomita et al . (1991) J. Fairy Sci. 74:4137-4142.
Vorland et al. (1999) APMIS. 107:971-981.
Wieprecht et al. (1997) FEBS Letters 417:135-140.
Zasloff et al. (1988) Proc. Natl. Acad. Sci. USA 85:910-913.
Rekdal Oystein
Sveinbjornsson Baldur
Svendsen John Sigurd
Vorland Lars
Alpharma AS
Dorsey & Whitney LLP
Russel Jeffrey Edwin
LandOfFree
Cytotoxic modified lactoferrin peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxic modified lactoferrin peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxic modified lactoferrin peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3460209